China’s pharmaceutical sector is undergoing a major transformation, driven by innovation, demographic shifts, and bold regulatory reforms. As urbanization and an aging population fuel demand, top companies are leveraging R&D strength and strategic agility to lead in a rapidly evolving healthcare landscape.
Explore how China’s apparel sector, especially sportswear, continues to thrive in 2025, driven by innovation, strong R&D efforts, and digital engagement. Learn about key players like ANTA, Bosideng, and Lululemon, as they lead the market amid economic challenges and evolving consumer trends.
China’s technology industry is driving global innovation by integrating AI, expanding ecosystems, and developing semiconductors. Despite legislative changes and trade tensions, firms who engage in R&D and diversify their business models gain a competitive advantage in this ever-changing world.
The New Materials sector in China is currently dominated by foreign multinational companies, but the Chinese government’s strategic focus on the sector is encouraging home-grown challengers to invest in research and development to become more innovative. Read on to find out how the sector is evolving.
The market share of Chinese independent brands has risen from 35.8% in 2020 to 56.1% in the first five months of 2024. Read on to see which are succeeding and how they are doing so
How have the top companies in the food and beverage sector of this year’s China Company Transformation Indicator got ahead of their competitors?
Maturing mega- tech companies get to grips with boosting revenues and controlling costs as growth rates plateau. The future landscape could see a reshuffle, as long-term investment in R&D by less high-profile companies positions them for expansion.
IMD research places world leader Nike ahead of local rivals, but its podium position is under threat as local sentiment and quality products build a growing loyalty for national apparel brands.
IMD research reveals the top four key attributes of successful companies in the Chinese pharma sector, including their global and local strategies as well as their acquisitions and investment in local companies, best cost logistics and production, and development of a robust pipeline of new innovative solutions, including oncology and weight-loss treatments.
While there is widespread concern that tensions around Taiwan might escalate into conflict, opinions vary on how this could be avoided. A recent Asia Society Switzerland debate heard the arguments for two different approaches.
Explore first person business intelligence from top minds curated for a global executive audience